Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1001 in Combination With Pembrolizumab and Chemotherapy in Stage 4 NSCLC
NCT06246110Phase 2Active, not recruiting
- Sponsor
- Eikon Therapeutics
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BDB001 in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Eikon Therapeutics. Primary endpoint: Adverse Events up to 2 years. Started Feb 2024; status: active, not recruiting.
02
Drugs
BDB001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06246110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246110.